Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
-2.55M
-
Total reported value, excl. options
-
$91.8M
-
Value change
-
-$38.9M
-
Put/Call ratio
-
0.5
-
Number of buys
-
53
-
Number of sells
-
-66
-
Price
-
$3.04
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2021
136 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2021.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 49.6M outstanding shares and own 60.8% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.68M shares), BlackRock Inc. (3.2M shares), GOLDMAN SACHS GROUP INC (2.28M shares), Camber Capital Management LP (2.05M shares), RENAISSANCE TECHNOLOGIES LLC (1.82M shares), ACADIAN ASSET MANAGEMENT LLC (1.75M shares), MILLENNIUM MANAGEMENT LLC (1.71M shares), Eversept Partners, LP (1.12M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (757K shares), and D. E. Shaw & Co., Inc. (736K shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.